Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics
, novel therapeutic avenues (such as antibody-drug conjugates, bispecific antibodies, DNA damage response inhibitors, and tumor microenvironment modulating agents) are reshaping precision oncology in CRC. Integrating multiomics profiling with dynamic biomarkers may enable durable activity and personalized treatment strategies.
Authors
- Rafael Grochot (ORCID: https://orcid.org/0000-0002-2156-9197)
- Patrick Reimann (ORCID: https://orcid.org/0000-0001-8387-3357)
- Thomas Winder
- Michela Bartolini
- Sandra Algaze
- Elisa Fontana
- Heinz-Josef Lenz
Institutions
- Sarah Cannon Research Institute (GB)
- University of Zurich (CH)
- Landeskrankenhaus Feldkirch (AT)
- USC Norris Comprehensive Cancer Center (US)
Publication Details
- Journal
- American Society of Clinical Oncology Educational Book
- Published
- 2026-04-24
- DOI
- https://doi.org/10.1200/edbk-26-516576
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00